Mankind Pharma Limited
Nippon India Mutual Fund increased its stake in Mankind Pharma from 1.45% to 2.07%, acquiring an additional 2,566,935 shares. The approximate value of the acquired shares is ₹609.19 crore, based on a share price of ₹2374.50.
A pharmaceutical company that develops, manufactures, and markets a diverse range of formulations across acute and chronic therapeutic areas alongside consumer healthcare products. Incorporated in 1995, the company operates through multiple distribution channels and disease segments within India's pharmaceutical market. Its portfolio spans prescription medicines, over-the-counter products, and wellness offerings designed to serve diverse patient populations and healthcare needs.
India's fifth-largest AMC with over Rs 6 lakh crore in AUM, backed by Japan's Nippon Life Insurance which holds majority stake. Formerly Reliance MF, rebranded in 2019 after Nippon's acquisition. Sailesh Raj Bhan has run the equity book for over two decades and is one of India's most experienced active managers. Known for sector rotational calls and a deep research bench.